AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 294 min read$ILMN

Illumina (NASDAQ:ILMN) reports sales below analyst estimates in Q3 2026 earnings, stock drops 16%

Illumina (ILMN) reported Q3 2026 revenue of $1.13B, missing estimates by 2.1%. Adjusted EPS of $1.44 beat estimates by 6.1%. The company raised full-year revenue guidance to $4.65B and EPS guidance to $5.43. Shares dropped 16% post-earnings.

Original reporting
finance.yahoo.com
Published Oct 29, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 8:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Illumina (NASDAQ:ILMN) reports sales below analyst estimates in Q3 2026 earnings, stock drops 16% — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ILMNBearishHigh
01

Why it matters

Traders will focus on whether the organic revenue shortfall reflects temporary demand softness or a broader slowdown, given the stock’s sharp post-report decline.

02

Market read

A same-report earnings print with a revenue miss and a large single-day drop creates a clear near-term re-pricing point for ILMN risk and positioning.

03

What to watch

Organic revenue growth was still positive (4.8% YoY) and profitability metrics (operating margin, free cash flow margin) improved, which could support stabilization after the initial selloff.

Relevance 9/10Novelty 8/10Timing: after-hours/next-session reaction to Q3 2026 earnings release

Background

Illumina reported Q3 2026 results with a revenue miss but profitability and EPS beats, alongside modest full-year guidance increases.

Company-level read

Ticker impact

$ILMNBearishHigh confidence
Context

Illumina missed Q3 2026 revenue expectations ($1.13B vs $1.15B consensus) while shares dropped 16% after the report.

Expected impact

Likely downside pressure as the market re-prices near-term demand/organic growth softness, even with improved profitability and guidance.

Evidence & confidence

The article attributes a 16% plunge to the Q3 revenue miss, while noting EPS and operating income beats and only modest guidance lifts.

Market effects

Sector

Sequencing and genomics equipment names may face renewed scrutiny on organic growth and clinical demand durability.

Regional

US healthcare and biotech/genomics sentiment likely pressured by the earnings reaction.

Global

Limited direct global spillover beyond sequencing demand expectations.

Counterpoint

What could challenge this read

The company beat on adjusted EPS and operating income and raised full-year revenue and EPS guidance, suggesting the revenue miss may be timing-related rather than structural.

Key entities

  • company
    Illumina

    Genomics company reporting Q3 2026 revenue miss, EPS/operating income beats, and raised full-year guidance.

Read at source← All news

StoryIllumina posts Q3 FY2026 results, raises full‑year guidance but shares tumble

Also covered by

5 outlets

Related articles

OCT 29
$ILMNMedAI 8/10

Illumina Q3 Earnings Call Highlights

Illumina reported Q3 operating cash flow of $419M and free cash flow of $378M. The company raised its 2026 revenue outlook to $4.64B-$4.66B and expects full-year EPS of $5.40-$5.45. Q4 revenue is projected at $1.22B-$1.24B. Illumina placed over 80 NovaSeq X instruments in Q3, with high demand driven by clinical diagnostics. The company also highlighted its BioInsight ecosystem and AI data opportunities, with financial visibility expected in 2027.

finance.yahoo.com6 min
OCT 29
$AMZNHighAI 9/10

After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN

AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, and ILMN reported earnings after hours. AMZN missed Q3 estimates and guided Q4 below consensus. TWLO beat Q3 and raised FY2026 outlook but fell. INTC beat Q3 but guided Q4 below consensus. SNDK beat and raised Q1 guidance. RDDT and RBLX fell on cautious guidance. PINS missed Q3 and guided Q4 below consensus. RIVN beat Q3 and raised full-year guidance. SBUX posted mixed Q4 results. ILMN missed Q3 revenue.

investing.com6 min
OCT 29
$ILMNMedAI 9/10

Illumina: Q3 Earnings Snapshot

Illumina Inc. (ILMN) reported Q3 net income of $220 million, or $1.43 per share, beating analyst estimates of $1.36 per share. Revenue was $1.13 billion, slightly below expectations of $1.14 billion. The company expects full-year earnings of $5.40-$5.45 per share and revenue of $4.64-$4.66 billion.

finance.yahoo.com3 min